Last edition
News about "Barth syndrome"
Stealth BioTherapeutics' Elamipretide NDA Resubmission Accepted for Review by US FDA
Stealth BioTherapeutics has announced that the US FDA has accepted for review its resubmitted New Drug Application for elamipretide to treat Barth syndrome, with a planned goal date of September 26, 2025.
Barth Syndrome | 22/08/2025 | By Mrinmoy Dey | 235
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members